Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ROS1-Mutated Inoperable Spindle Cell Sarcoma Treated With Repotrectinib-A Case Report.

JCO precision oncology·2026
Same author

A novel algae oil-based emulsion enhances chemotherapy outcome in human cancer models.

Prostaglandins, leukotrienes, and essential fatty acids·2026
Same author

Nationwide treatment patterns and outcomes of localised soft tissue sarcoma in Austria: real-world data from the Austrian Sarcoma Registry.

Journal of orthopaedic surgery and research·2026
Same author

FOS and FOSB Immunohistochemistry and Molecular Testing Reveal Novel Patterns in Proliferative Fasciitis and Myositis, FOSB Rearrangement in Proliferative Funiculitis, and FOSL1 :: RELA Fusion in Pediatric Proliferative Fasciitis.

The American journal of surgical pathology·2026
Same author

Feasibility and workflow analysis of confocal microscopy in robot-assisted prostatectomy.

BJU international·2026
Same author

Malignant vascular neoplasms of the distal female genital tract: a series of 19 cases emphasizing unusual features and diagnostic challenges.

Histopathology·2026
Same journal

Keratins and desmosomal proteins: Utility for molecular subtype identification in muscle-invasive bladder cancer.

Virchows Archiv : an international journal of pathology·2026
Same journal

Immunohistochemical profiling of ampullary carcinoma: Molecular subtypes, prognostic markers, and the role of Claudin-18.

Virchows Archiv : an international journal of pathology·2026
Same journal

Adult sialoblastoma harbouring FGFR2 p.C382R gene mutation.

Virchows Archiv : an international journal of pathology·2026
Same journal

Response to: comment on "FOXL2 expression in dysgenetic gonads supports the diagnostic possibility of ovotesticular differences of sex development".

Virchows Archiv : an international journal of pathology·2026
Same journal

Role of INSM1 expression in the diagnostic work-up of pancreatic acinar cell carcinoma with special reference to the differential diagnosis with neuroendocrine tumor.

Virchows Archiv : an international journal of pathology·2026
Same journal

Mismatch repair protein deficiency (MMRd) and high microsatellite instability (MSI-H) in gastrointestinal stromal tumour (GIST) - a case report and review of the literature of this exceedingly rare phenotype.

Virchows Archiv : an international journal of pathology·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Gastrointestinal stromal tumors.

Bernadette Liegl-Atzwanger1, Jonathan A Fletcher, Christopher D M Fletcher

  • 1Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Virchows Archiv : an International Journal of Pathology
|February 19, 2010
PubMed
Summary
This summary is machine-generated.

Gastrointestinal stromal tumors (GISTs) are now treatable due to understanding their biology and targeted therapies. Research explores GIST pathogenesis, diagnosis, and resistance to treatments like imatinib.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 16, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Pathology

Background:

  • Gastrointestinal stromal tumors (GISTs) have transformed from poorly understood to treatable entities.
  • GISTs serve as a model for molecularly targeted therapy in solid tumors.
  • Activating mutations in KIT or PDGFRA genes drive GIST development in ~85% of cases.

Purpose of the Study:

  • To review GIST pathogenesis, morphologic evaluation, and diagnostic tools.
  • To discuss risk assessment, molecular analysis, and emerging treatments.
  • To address challenges in diagnosing KIT-negative GISTs and managing imatinib resistance.

Main Methods:

  • Literature review focusing on GIST biology, targeted therapies, and diagnostic advancements.
  • Analysis of diagnostic challenges including immunohistochemistry and molecular testing.
  • Examination of mechanisms of secondary imatinib resistance.

Main Results:

  • Understanding GIST mutations (KIT/PDGFRA) enables targeted therapies like imatinib and sunitinib.
  • KIT (CD117) immunohistochemistry is crucial but has limitations.
  • Secondary resistance to imatinib is an increasing clinical challenge.

Conclusions:

  • GISTs are a paradigm for targeted therapy, highlighting both successes and limitations.
  • Accurate diagnosis, risk assessment, and molecular analysis are vital for effective GIST management.
  • Further research is needed to overcome treatment resistance and improve patient outcomes.